Rare Disease Nonprofits: De-Risk Development With Orphan Drug Designation And Early Talks With The FDA

By H. Greg Thomas, Ph.D., vice president of R&D, Kiel Laboratories

Rare diseases affect over 30 million Americans, yet most of the 7,000 known conditions lack FDA-approved therapies.^1,2 Nonprofits are essential to bridging this gap, driving early research, advancing proof-of-concept studies, and aligning academic, industry, and patient stakeholders. Nonprofit-led orphan drug programs illustrate that breakthroughs in rare disease often begin with a mission, not a market.

FDA Orphan Drug designation (ODD) offers a powerful strategic tool that reduces regulatory uncertainty, focuses limited resources, and aligns programs with FDA expectations from the outset. When integrated early, ODD helps transform mission-driven efforts into feasible development pathways, particularly amid regulatory shifts in 2026 toward more personalized therapies. ODD does not lower evidentiary standards for safety or effectiveness, nor does it guarantee marketing authorization, but it does provide a framework for development pre-submission.³

The 2026 Rare Disease Regulatory Landscape

In early 2026, the FDA further strengthened its rare disease regulatory infrastructure. The current regulatory landscape for orphan drugs emphasizes the FDA’s push toward more flexible pathways for rare disease development, particularly benefiting nonprofits and academic partners:

• The FDA’s Rare Disease Innovation Hub agenda drives cross-center collaboration between CDER and CBER, focusing on novel endpoints, real-world evidence, and adaptive trials for small patient populations.⁴
• The Individualized Therapies Guidance supports genome editing and RNA-based products by relying on mechanistic rationale and natural history data, sidestepping traditional randomized trials that are impractical for ultra-rare conditions.⁵
• Congress extended the Rare Pediatric Disease Priority Review Voucher (PRV), a non-dilutive funding lifeline for nonprofits targeting ultra-rare pediatric cases.⁶
• Expanded pilots like the Rare Disease Endpoint Advancement (RDEA) and Support for Clinical Trials Advancing Rare Disease Therapeutics (START) provide milestone-based FDA feedback to streamline early development.^5,7
• The Consolidated Appropriations Act (H.R. 7148) enhances orphan incentives, bolstering resource-limited programs. Vouchers may be sold or transferred and have historically commanded significant market value, often selling for prices between $100 million and $200 million. This makes PRV eligibility a potentially important consideration in financing or partnering strategies.^{8, 9}

Building A Nonprofit ODD Strategy

To take advantage of the benefits of ODD, nonprofits should start strategic planning early. These steps can help:

• Assess ODD eligibility immediately. Eligibility assessment should begin once a credible disease-mechanism link is established.
• Define disease precisely. The FDA places significant weight on disease definition; while orphan subsets may be appropriate, they must be supported by a clear drug-specific scientific rationale.
• Align evidence. Integrate disease biology, mechanism of action, and available data into a coherent narrative that explains why the therapy should plausibly benefit patients, despite inherent data limitations. This includes clearly linking the underlying pathophysiology to the proposed intervention, demonstrating that the mechanism meaningfully engages a key disease driver, and anchoring claims in credible nonclinical, clinical, or natural history data. For rare and ultra-rare conditions where traditional trials may be limited, the FDA increasingly expects integrated cross-functional evidence, not disconnected data silos.
• Leverage FDA meetings. These offer an opportunity to gain clarity on definitions, plans, and evidence. Examples may include:
  • Pre‑ODD (concept definition and eligibility framing) Use early FDA interactions, such as Office of Orphan Products Development (OOPD) consultations or Type C meetings, to stress-test the proposed disease definition and confirm orphan eligibility.¹⁰ At this stage, discussions should focus on whether the condition or subset is scientifically distinct, how the mechanism of action aligns with disease biology, and whether existing nonclinical or natural history data are sufficient to support a medically plausible benefit narrative. Early FDA feedback helps avoid misaligned orphan requests and ensures that the designation strategy is grounded in the FDA’s current thinking before submission.
  • Pre‑IND (development pathway alignment). Leverage formal pre-IND meetings to align on the overall development plan, including nonclinical requirements, first-in-human study design, dose rationale, endpoint selection, and the role of natural history or external control data. For rare and ultra-rare diseases, these meetings are particularly important to discuss alternative evidentiary approaches, feasibility constraints, and acceptable risk-based strategies. Clear agreement or documented feedback at this stage strengthens the orphan rationale, informs CMC and clinical investments, and reduces the risk of preventable IND delays.
  • Post‑IND (clinical execution and evidence optimization) Use Type B (e.g., end‑of‑phase meetings) and Type C interactions to refine clinical strategy as data emerges. These meetings support alignment on endpoint performance, trial adaptations, confirmation of patient populations, and plans for accelerated approval, confirmatory evidence, or other appropriate regulatory pathways, including expanded access. For nonprofit and mission‑driven sponsors, post‑IND meetings help ensure that limited resources are focused on evidence generation most likely to meet FDA expectations while preserving flexibility as scientific understanding evolves.
• Plan CMC early. Manufacturing considerations frequently become development-limiting risks; early CMC planning is essential to preserve optionality and avoid downstream delays, especially for nonprofit sponsors.¹¹

Key Resources For Nonprofits

There is a robust ecosystem of public, private, and mission-driven resources that supports regulatory planning, clinical development, manufacturing, and patient engagement. Consider using the resources below to extend funding while maintaining regulatory credibility:

• FDA tools: OOPD consultations, grants, RDEA/START pilots
• Funding: NIH institutes, National Center for Advancing Translational Sciences (NCATS), state innovation funds, and disease foundations offering non-dilutive support
• Academic and consortium partnerships: Access to disease experts, validated models, and research networks
• Advocacy‑led infrastructure: Patient registries, biobanks, and caregiver networks that support endpoint development and recruitment

Ultra-Rare Focus: A Shared Domain For Nonprofits, Patients, And Academia

Ultra-rare disease programs (<1,000 patients) commonly require customized approaches, including external or historical controls, adaptive or single arm trials, greater reliance on patient reported outcomes, and explicit benefit–risk discussion appropriate to severe disease.

Key factors to consider include:

• academic leadership in disease definition, biology, and translational science¹²
• nonprofit coordination and funding of natural history and early clinical work
• patient and caregiver insight to define meaningful endpoints and feasible trials; the FDA increasingly expects thoughtful incorporation of patient experience data¹³
• regulatory framing, including orphan designation strategy and early FDA engagement.

The central question is not whether a disease qualifies as orphan or ultra-rare but whether an organization is prepared to help build the scientific, clinical, and regulatory foundation that ultra-rare development requires. In practice, mission-driven nonprofits and academic consortia often function as the de facto sponsor, coordinating evidence generation, partnerships, and FDA engagement across a fragmented ecosystem.

Well-established examples include the Cystic Fibrosis Foundation’s venture-philanthropy model, which catalyzed multiple FDA-approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, the Spinal Muscular Atrophy (SMA) Foundation’s role in early translational development that enabled rapid industry partnering, and Fondazione Telethon’s successful advancement of a gene therapy through full FDA approval.^14-16 Success in these efforts depends on disciplined data development, strong collaborations, and early, sustained FDA interaction. Orphan Drug designation provides important structure and leverage, but it frames risk — it does not eliminate it.

Treat Orphan Drug Designation As The Beginning, Not The End

For nonprofit organizations, ODD should mark the start of a disciplined, forward-looking regulatory strategy, not its conclusion. When pursued early and integrated into development planning, ODD can reduce regulatory uncertainty, focus limited resources, and help establish a viable path toward FDA review. In an environment where scientific promise alone is rarely sufficient, early and sustained regulatory alignment remains one of the most powerful tools nonprofits have to translate mission-driven research into therapies that ultimately reach patients.

Realizing this potential often requires more than internal effort alone. Working with experienced partners can further strengthen execution by bringing the regulatory and technical expertise needed to navigate complex requirements, anticipate risks, and advance development efficiently. For organizations with limited internal infrastructure, external expertise can be critical in moving from designation to a well-aligned development program.

References:

1. U.S. Food and Drug Administration. Rare Diseases at FDA. https://www.fda.gov/patients/rare-diseases-fda
2. Fermaglich, L.J., & Miller, K.L. (2023). A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet Journal of Rare Diseases, 18(1), 163. https://doi.org/10.1186/s13023-023-02790-7
3. U.S. Food and Drug Administration. Orphan Drug Act – Relevant Excerpts. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts
4. U.S. Food and Drug Administration. (2026). Rare Disease Innovation Hub strategic agenda. U.S. Department of Health and Human Services. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub
5. U.S. Food and Drug Administration. (2026). Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause: Draft Guidance for Industry. U.S. Department of Health and Human Services. https://www.fda.gov/media/191247/download
6. U.S. Food and Drug Administration. (2026). Rare Pediatric Disease Designation and Priority Review Voucher Programs. U.S. Department of Health and Human Services. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs
7. United States, Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027. U.S. Department of Health and Human Services, 2021. www.fda.gov/media/151712/download
8. United States, Congress. Consolidated Appropriations Act, 2026. Public Law No. 119-75, Sec. 6604, 3 Feb. 2026. Congress.gov. www.congress.gov/
9. Davies C, Landmon CA. New FDA Drug Reforms: Congress Extends Voucher Incentive, Clarifies Orphan Exclusivity and Provides Greater Transparency for Q1/Q2 Generic Approvals. National Law Review. February 18, 2026. https://natlawreview.com/article/new-fda-drug-reforms-congress-extends-voucher-incentive-clarifies-orphan
10. United States, Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products: Guidance for Industry. U.S. Department of Health and Human Services, 2024. www.fda.gov/media/172311/download
11. United States, Food and Drug Administration. IND Submissions for Investigational Medicinal Products: Chemistry, Manufacturing, and Controls (CMC) Information. U.S. Department of Health and Human Services, 2023. www.fda.gov/media/164322/download
12. National Center for Advancing Translational Sciences. Rare Diseases Clinical Research Network (RDCRN). National Institutes of Health, 2024. https://ncats.nih.gov/research/research-activities/rdcrn  
13. United States, Food and Drug Administration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making. U.S. Department of Health and Human Services, 2023. www.fda.gov/media/166830/download
14. Cystic Fibrosis Foundation. “Our Venture Philanthropy Model.” Cystic Fibrosis Foundation, 2026. www.cff.org/about-us/our-venture-philanthropy-model
15. Chong, Li Chuin et al. “Drug Discovery of Spinal Muscular Atrophy (SMA) from the Computational Perspective: A Comprehensive Review.” International journal of molecular sciences vol. 22,16 8962. 20 Aug. 2021. https://doi.org/10.3390/ijms22168962  
16. U.S. Food and Drug Administration. (2025, December 9). FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome. U.S. Department of Health and Human Services. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome

About The Author:

As Vice President of Research & Development, H. Greg Thomas oversees R&D activities including QA, legal, and regulatory affairs. He brings over 50 years of experience in pharmaceutical R&D, having first joined Kiel Laboratories in 1998 as director of laboratory services before becoming VP in 2000. Previous employers include Solvay Pharmaceuticals, Emory, and the VA. Greg is an extensively published researcher and peer reviewer. He earned his B.A. from University of West Georgia and Ph.D. from UGA College of Pharmacy.